期刊文献+

Targeting the elabela/apelin-apelin receptor axis as a novel therapeutic approach for hypertension 被引量:2

原文传递
导出
摘要 Hypertension is the leading risk factor for global mortality and morbidity and those with hypertension are more likely to develop severe symptoms in cardiovascular and cerebrovascular system,which is closely related to abnormal renin-angiotensin system and elabela/apelin-apelin receptor(APJ)axis.The elabela/apelin-APJ axis exerts essential roles in regulating blood pressure levels,vascular tone,and cardiovascular dysfunction in hypertension by counterbalancing the action of the angiotensin II/angiotensin II type 1 receptor axis and enhancing the endothelial nitric oxide(NO)synthase/NO signaling.Furthermore,the elabela/apelin-APJ axis demonstrates beneficial effects in cardiovascular physiology and pathophysiology,including angiogenesis,cellular proliferation,fibrosis,apoptosis,oxidative stress,and cardiovascular remodeling and dysfunction during hypertension.More importantly,effects of the elabela/apelin-APJ axis on vascular tone may depend upon blood vessel type or various pathological conditions.Intriguingly,the broad distribution of elabela/apelin and alternative isoforms implicates its distinct functions in diverse cardiac and vascular cells and tissue types.Finally,both loss-of-function and gain-of-function approaches have defined critical roles of the elabela/apelin-APJ axis in reducing the development and severity of hypertensive diseases.Thus,targeting the elabela/apelin-APJ axis has emerged as a pre-warning biomarker and a novel therapeutic approach against progression of hypertension,and an increased understanding of cardiovascular actions of the elabela/apelin-APJ axis will help to develop effective interventions for hypertension.In this review,we focus on the physiology and biochemistry,diverse actions,and underlying mechanisms of the elabela/apelin-APJ axis,highlighting its role in hypertension and hypertensive cardiovascular injury and dysfunction,with a view to provide a prospective strategy for hypertensive disease therapy.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2022年第9期1019-1026,共8页 中华医学杂志(英文版)
基金 General Program and the National Major Research Plan Training Program of the National Natural Science Foundation of China(No.81770253 and No.91849111) the Shanghai Sailing Program(No.20YF1444100)。
  • 相关文献

参考文献2

二级参考文献3

共引文献50

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部